Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy category |
|
Routes of administration | Inhalation (MDI) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 6.5 hours approximately [1][2][3][4] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.205.960 |
Chemical and physical data | |
Formula | C17H21NO4 |
Molar mass | 303.358 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Fenoterol is a β adrenoreceptor agonist. It is classed as sympathomimetic β2 agonist and an inhaled bronchodilator asthma medication.
Fenoterol is produced and sold by Boehringer Ingelheim as Berotec N and in combination with ipratropium as Berodual N.
It was patented in 1962 and came into medical use in 1971[5] but, in the 1980s, concerns emerged about its safety and its use being associated with an increased risk of death (see below).